-+ 0.00%
-+ 0.00%
-+ 0.00%
Jazz wins FDA approval for Ziihera regimens in first-line HER2+ gastroesophageal cancer, triggering USD 250 million Zymeworks milestone
Share
Listen to the news
Jazz wins FDA approval for Ziihera regimens in first-line HER2+ gastroesophageal cancer, triggering USD 250 million Zymeworks milestone
  • FDA cleared two first-line Ziihera (zanidatamab-hrii) regimens for unresectable or metastatic HER2+ gastroesophageal adenocarcinoma.
  • Jazz can market Ziihera with Tevimbra (tislelizumab) and chemotherapy for all HER2+ patients, regardless of PD-L1 status.
  • Zymeworks will receive a USD 250 million milestone from Jazz, remaining eligible for up to USD 1.3 billion more.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608251023PRIMZONEFULLFEED9815655) on August 25, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending